Corteva, Inc.
- Open
- 84.04
- Day high
- 85.28
- Day low
- 83.72
- Prev close
- 83.90
- Volume
- 5.6M
- Mkt cap
- $56.5B
- P/E (TTM)
- 56.1
- EPS (TTM)
- $1.51
- P/B
- 2.2
- P/S
- 3.2
- Yield
- 0.85%
- Per share
- $0.72
Corteva, Inc. (CTVA) is a Basic Materials company listed on NYSE. The stock is up 14% over the past year. Drillr has 2 published research articles covering CTVA.
Corteva, Inc. (CTVA) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 10 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CTVA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 31, 2026 | $2.24 | $2.30 | +2.7% | $6.4B | -3.3% |
| May 6, 2026 | $1.17 | $1.50 | +28.2% | $4.9B | +5.7% |
| Feb 3, 2026 | $0.22 | $0.22 | -1.3% | $3.9B | -7.8% |
| Aug 6, 2025 | $1.89 | $2.20 | +16.4% | $6.5B | +3.0% |
| Feb 5, 2025 | $0.31 | $0.32 | +2.5% | $4.0B | -1.5% |
| Jul 31, 2024 | $1.73 | $1.83 | +5.8% | $6.1B | -0.6% |
| May 1, 2024 | $0.82 | $0.89 | +8.1% | $4.5B | -3.4% |
| Jan 31, 2024 | $0.06 | $0.15 | +155.4% | $3.7B | +2.8% |
| Aug 3, 2023 | $1.58 | $1.60 | +1.3% | $6.0B | +88.7% |
| May 3, 2023 | $0.93 | $1.16 | +24.7% | $4.9B | -25.6% |
| Feb 1, 2023 | $0.06 | $0.16 | +166.7% | $3.8B | +0.9% |
| Nov 3, 2022 | $-0.23 | $-0.12 | +47.8% | $2.8B | +7.1% |
CTVA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 4, 2026 | Policinski Christopher J.director | Grant | 413 | $78.71 |
| Aug 4, 2026 | Giesselman Janet Plautdirector | Grant | 98 | $78.71 |
| Aug 4, 2026 | Nayyar Nayaki Rdirector | Grant | 413 | $78.71 |
| May 4, 2026 | Giesselman Janet Plautdirector | Grant | 96 | $81.01 |
| May 4, 2026 | Engel Klaus Adirector | Tax | 906 | $81.01 |
| May 4, 2026 | Lutz Marcos Mdirector | Tax | 906 | $81.01 |
| May 4, 2026 | Nayyar Nayaki Rdirector | Grant | 401 | $81.01 |
| Apr 30, 2026 | Engel Klaus Adirector | Grant | 2,350 | — |
| Apr 30, 2026 | Gilson Jean-Marcdirector | Grant | 2,350 | — |
| Apr 30, 2026 | Nayyar Nayaki Rdirector | Grant | 2,350 | — |
| Apr 30, 2026 | Lutz Marcos Mdirector | Grant | 2,350 | — |
| Apr 30, 2026 | EVERITT DAVID Cdirector | Grant | 2,350 | — |
| Apr 30, 2026 | Preete Kerry Jdirector | Grant | 2,350 | — |
| Apr 30, 2026 | Giesselman Janet Plautdirector | Grant | 2,350 | — |
| Apr 30, 2026 | Ward Patdirector | Grant | 2,350 | — |
Source: CTVA SEC Form 4 filings, latest Aug 4, 2026. For informational purposes only — not investment advice.
See the full CTVA insider & 13F page →CTVA research & analysis
Deere (DE), Ridley (RIDYF): Crop Growers Defer Machinery, Ranchers Buy
Deere, AGCO, CNH and Ridley told July-August 2026 calls that fertiliser and diesel costs froze crop-grower equipment budgets while beef-funded livestock customers kept spending.
AGCOBCPCCNHCF, MOS, NTR: Iran Supply Squeeze Drives Fertilizer Prices — Top 3 Ranked by Conviction
Trump's anti-gouging pledge amid Iran tensions spotlights US fertilizer producers' upside from West Asia supply squeezes. CF, MOS, and NTR lead with strong financials and exposure, ranked for conviction amid tightening markets.
CFMOSNTR
Corteva, Inc. company profile
Overview
Corteva, Inc. (NYSE:CTVA) is a leading agricultural technology company that emerged as an independent entity in 2019 following its spin-off from DowDuPont. The company was formed through the combination of Dow AgroSciences and DuPont Pioneer, bringing together over 200 years of combined agricultural innovation heritage. Headquartered in Indianapolis, Indiana, Corteva operates globally across North America, Latin America, Europe, Middle East, Africa, and Asia Pacific, serving farmers worldwide with advanced seed genetics and crop protection solutions.
Business
Corteva operates in the agricultural inputs industry, which provides essential products that enable farmers to grow crops more effectively and efficiently. The company operates through two primary business segments that work synergistically to support agricultural productivity. The Seed segment represents approximately 56% of total revenue and focuses on developing and commercializing advanced crop genetics. This business develops corn, soybean, sunflower, canola, and other crop varieties with enhanced traits such as herbicide tolerance, insect resistance, and improved nutritional profiles. The segment's flagship technologies include Enlist E3 soybeans, which provide tolerance to multiple herbicides, and various corn hybrids optimized for different growing conditions. Beyond traditional breeding, the segment increasingly incorporates biotechnology, gene editing, and digital agriculture tools to help farmers optimize seed selection and maximize yields. The Crop Protection segment accounts for roughly 44% of revenue and produces chemicals that protect crops from weeds, insects, diseases, and other agricultural pests. This includes herbicides (weed killers), insecticides (pest control), fungicides (disease prevention), and nitrogen stabilizers that improve fertilizer efficiency. Key products include Enlist herbicides, which work in conjunction with Enlist-trait seeds, and a growing portfolio of biological crop protection products that offer more sustainable alternatives to traditional chemistry. The company is increasingly focused on biologicals - naturally derived products that enhance crop health and protection - which represents a fast-growing segment within both divisions. Corteva also generates revenue through technology licensing, where it out-licenses its genetic traits and technologies to other seed companies globally, creating recurring royalty income streams.
Revenue model
Corteva generates revenue through multiple complementary business models that capitalize on different aspects of the agricultural value chain. The primary revenue driver is direct product sales to farmers, distributors, and agricultural retailers. In the seed business, farmers purchase new seed each planting season, creating recurring annual demand. Seed pricing typically commands premium rates due to the advanced genetics and traits that directly impact crop yields and farmer profitability. The crop protection business operates on a similar model, with farmers purchasing chemicals seasonally based on pest pressure, weather conditions, and crop protection needs. This segment faces more pricing pressure due to generic competition and commodity-like characteristics of some products, though newer biological and differentiated chemistry products maintain higher margins. A growing and strategically important revenue stream comes from technology licensing and royalties. Corteva licenses its genetic traits, such as herbicide tolerance and insect resistance, to other seed companies worldwide. This creates high-margin recurring revenue with minimal additional production costs. Royalty income has grown 40% year-over-year as technologies like Enlist E3 achieve broader market penetration. Several factors significantly impact Corteva's margins and profitability. Commodity crop prices directly influence farmer purchasing power - when corn, soybean, and other crop prices are high, farmers invest more in premium seeds and crop protection. Weather patterns affect both demand timing and product effectiveness, with extreme weather potentially reducing application windows or creating increased pest pressure. Regulatory approvals for new traits and chemistry can take years and significantly impact market access, particularly for international markets. Generic competition in crop protection puts downward pressure on pricing, especially for older chemistry, while input cost inflation for raw materials and energy affects production costs. The company's margin expansion strategy focuses on shifting toward higher-value differentiated products, biologicals, and technology licensing to offset these pressures.
Competitive moat
Corteva possesses a moderate to strong competitive moat built primarily around intellectual property, regulatory barriers, and scale advantages, though the strength varies significantly between its two business segments. The seed business demonstrates the stronger moat characteristics, with extensive patent portfolios protecting genetic traits and germplasm that can take 8-12 years to develop and commercialize. The company's breeding programs and biotechnology capabilities create ongoing innovation advantages, while regulatory approvals for new traits create significant barriers to entry. The technology licensing model represents perhaps the strongest moat element, as successful genetic traits become industry standards that generate recurring royalty income with minimal marginal costs. Enlist E3 soybean technology, for example, has achieved 65% market penetration in the U.S., creating a durable competitive advantage through network effects - the more farmers use the technology, the more valuable the associated herbicide system becomes. However, the crop protection business faces more significant competitive pressures. While Corteva maintains advantages in new product development and biologicals, much of the traditional chemistry market has become commoditized as patents expire and generic manufacturers enter. The company's scale provides some advantages in regulatory compliance, global distribution, and R&D investment, but these are not insurmountable barriers. The primary competitive threats come from other agricultural giants like Bayer, Syngenta, and BASF, which have similar scale and capabilities. Additionally, generic manufacturers in crop protection and emerging biotechnology companies developing next-generation agricultural technologies pose ongoing challenges. The rise of gene editing technologies like CRISPR could potentially democratize crop development, reducing some of Corteva's breeding advantages. Climate change and evolving regulatory landscapes around pesticides and GMOs could also disrupt traditional competitive positions, making the company's shift toward biologicals and sustainable technologies increasingly critical for maintaining its moat.
Risks & safety
Corteva demonstrates a strong financial position with adequate margin of safety, though seasonal cash flow patterns require careful management. • Debt and Solvency: Very conservative debt levels with debt-to-equity ratio of 0.17, total debt of approximately $4.1 billion against $24.0 billion in equity. Strong current ratio of 1.44 indicates solid short-term liquidity. • Cash Position: Maintains $2.0-3.1 billion in cash and short-term investments, providing substantial financial flexibility. However, agricultural seasonality creates significant working capital swings, with negative free cash flow in Q1 ($-2.2 billion) recovering strongly by year-end. • Valuation Metrics: Trading at reasonable multiples with P/E of 16.5x (Q1 2025), though this varies significantly due to seasonal earnings patterns. EV/EBITDA of 10.1x appears reasonable for a mature agricultural company with growth prospects. • Operational Cash Generation: Strong underlying cash generation capability, with full-year 2024 operating cash flow of $2.1 billion and free cash flow of $1.5 billion, demonstrating the business's ability to generate substantial cash returns despite seasonal volatility. • Other Considerations: Commodity exposure creates earnings volatility, but diversified geographic presence and balanced portfolio between seeds and crop protection provide some stability. Return on equity of 3.8% appears modest but reflects the capital-intensive nature of agricultural R&D.
Recent development
Over the past several years, Corteva has undergone a significant strategic transformation focused on shifting from being a technology buyer to a technology seller. This pivot emphasizes maximizing returns from the company's substantial R&D investments through expanded licensing arrangements and royalty generation. The company has successfully grown its royalty income by 40% year-over-year as key technologies like Enlist E3 soybeans achieve broader market penetration. The company has made substantial investments in biologicals, targeting $1 billion in biological revenue by the end of the decade. This includes acquisitions of companies like Symborg and Stoller, as well as internal development of biological crop protection and enhancement products. Biologicals represent a strategic shift toward more sustainable agricultural solutions that can command premium pricing while addressing growing regulatory and consumer preferences. Digital agriculture and precision farming have become increasingly important focus areas, with Corteva developing digital tools that help farmers optimize seed selection, application timing, and field management practices. These digital solutions create additional value-added services beyond traditional product sales. The company has also been developing new crop platforms beyond its traditional corn and soybean focus. Management has highlighted significant opportunities in hybrid wheat (potentially $1 billion revenue opportunity) and winter canola as future growth drivers. These represent efforts to expand addressable markets and reduce dependence on traditional row crops. Geographic expansion remains a priority, particularly in Brazil and other Latin American markets where Corteva sees substantial growth opportunities. The company has been investing in local breeding programs and expanding its trait licensing arrangements to capture more value from these high-growth agricultural markets. Cost management through the "controlling the controllables" program has been another key strategic initiative, targeting $400 million in annual cost improvements while maintaining R&D investment levels necessary for long-term competitiveness.
CTVA company profile · for informational purposes only — not investment advice.
Track CTVA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free